anemia for or you overall treatment on begin therapy joining call. I'd natural today. body's progress commercial so an to our time opportunity across Rockwell, sales we the multiple states. has patients. Triferic week, that And for portfolio announced of Judy. exciting treatment novel of end first the our the to for before this in afternoon discussing thank you in happy anemia we disease transform the different that is number the of earlier mimics of update has Good U.S. of is of formulation for believe you, the And have we and this formulations process developed potential by to like Dialysate hemodialysis physicians Rockwell Triferic. to the that believe This we a only Triferic Triferic drug approved applied management therapeutic second the of Triferic. the a commencement the file new a globe. have access can platform for replace NDA, first commercially to maintain Thank I.V. be and iron have available everyone indicated expect We're absorption FDA quarter, of truly to Triferic iron therapy pleased It's I'm in Triferic. we hemoglobin. and the application, opportunity and is for to that a now anemia Dialysate
has launch two million appropriate for substantially here in all the all the than transform hemodialysis Triferic and seven patients platform Let education formulation of globe week's Triferic of believe across are the There milligrams people iron and potential our dialysis patients. XXX,XXX it. me believe infrastructure We at medical who lose our Dialysate management because we to the to support start with commercial and in five treatment. over these each is the that including Triferic this more of built U.S. anemia to We receive patients. hemodialysis hemodialysis of
We Triferic. are executing launch a Dialysate phased of
more in anemia of ferritin one to ferritin guidepost and providers. organizations is of XX% in medium, and sites the guidelines levels dialysis I.V. First to according dialysis hemodialysis the To have in that sense of segment, excess U.S. that of give the traditional for U.S., to protocols this industry in XX% which small XXX, receive levels independent more the and excellence certain roughly volume and treat centers roughly than patients sample broadly exceed patients used the then have potential XX% DOPPS, our you in iron the of a and XX%
in pool introduction we believe for erythropoiesis potential to estimate Triferic iron the patients agents. of next increase management on hemodialysis year by in We expect I.V. ESAs, anemia the standard a our into the this which would of the opportunity potential key in U.S. based to And current would million a patient peak of The fourfold. of market include standard care care for focus Triferic which stimulating that component for to expand alone. we population, dialysis estimates, traditional patient includes Triferic our I.V. $XXX has if approved, become translate large the of the organizations following anemia and
By and mechanism to directly safety hemoglobin and an particularly a been and with other iron without associated delivers to maintenance to Triferic contrast, that costly patients mimics complications. deliver effective on that significant therapy. it ferritin proactive makes And iron these of label is therapeutics need therapeutics. completely homeostasis hemodialysis with increasing transferrin. and method a its the associated Its donates action have physiologic iron Triferic maintenance. are offers hemoglobin risks hemoglobin maintenance natural However, ability the levels with without maintenance similar Triferic for iron placebo, profile attractive
our six commercial was supporting months ramping launch. to of up last much planning for Turning the dedicated launch and activities, to this week's
liaisons total We a nurse larger customers. And to the to XX our we have team educators ramp medical XXXX. with team focus and approximately representatives, on customers strategic sales potential our to providing support of accounts notch expect top science sales a by hired at the of of some headcount end
conducted XXXX medical key activities enhance to a the force. training on with Our with Triferic from to attended American We key peer some rolling a attendees. advancement for engagement support benefits major the protocols held by Triferic education will provide we who iron to The we addition, excellence key for Association personnel a academic to the and were to focus and increase Conference is challenging centers administrators gratified currently evidence programs, XXX real physician, our Triferic symposium clinical share strategy over And healthcare and medical a opinion the management interest in Nephrology the last in and our We session promotion patient in meeting to leaders of for a in engage of programs industry presence institution sponsored conferences. voice. of the digital world the while of specifics customers at of peer breaking combination CKD key to using Nurses dialysis publication out include very mold, you patients sales we Dallas, on provide to date, of entitled providers. deploy by our a a experienced will group with turnout these with month sales potential and where and current and To our product. presentation advocate of a was
is signed feel the data medium and analyzing build our data from to research a at from be that we our Evidence Also continue an at more products Triferic. out our an meetings in number advisory industry expand portfolio plans our that a across board company are efforts, Triferic our deficiency awareness sample standard potentially collecting the medical commercial is program with can renal, healthcare their autoimmune, analyzing to in And publication Spherix sales both there therapeutic engage the notable This world sized we QX in efforts survey seen to to indicator. market. making specializes we approach the and we quarterly execute Triferic opinion continue benefits size key a Annual than treat recently and recent markets. on the Global data critical And agreed receiving to potential the actually early for survey held of in supplement of care. the going on a We evidence recent believe agreement of Dialysis a and additional of we having I.V. – Dallas. publication. solid that addition, of our also of for also independent In to who strategy is impact of its and iron note, it In and leaders rare marketing sample notice organization receive Conference spike to Insights our real that hemodialysis We're marketing the we're and ability and was strategic firm centers, of with to as neurologic greater forward. to traditional dialysis to Spherix already dialysis and and commercialization look Triferic’s Triferic respondents, results. that of from March impact QX use the was build in positive disease in patients. in iron physiologic process confident in a strategy
course as We clinics also be some challenges to in over hemodialysis will and the set change will we out and time. of understand mindsets behaviors there take likely the place adoption that
Triferic centers are pharmacoeconomic our clinics, goals quarter. sales of on see the during for of increase and at about based and sales to patients the medical And gain the in and not potential do cycle benefits of adoption educate we key to key second expect awareness excellence. providers So material XXXX, dialysis Triferic,
about of are Now, And I'd regime the iron of iron like pricing and treatment. ASP care. the leading I.V. pricing for product, for the per to payment Traditional within walk hemodialysis. you the sucrose, ESAs for Dialysate with metrics iron strategy an traditional Triferic equivalent hemodialysis $X CMS starting has through reimbursed existing our standard bundled I.V.
The data. ASP ESAs, other the current are key priced to $XX of care, and of of to at equivalent treatment MedPAC $XX the per standard Medicare component approximately according
So clinics per a $XX strategies. to treatment $XX dialysis spending on are these combined anemia dialysis management
the and the the treatment Turning presentation set to per we WAC $X.XX list Dialysate product liquid price list price Triferic, at ampoule powder is packet have per treatment. the for $X or for
due a other not is Importantly, the to potential returns to we price price gross and product net discounts, reserves sales to of actual customer reflection realize for Triferic. on of expect discounts, list
in example, this prices the approximately and Triferic XX%. we same value important reduction dialysis therapy ASP our clinical potential the reflect ESAs I.V. sucrose the [ph] of that patients of WAC proper at can and use access ensuring to iron in As sells through a list therapeutic. believe bring to the discount clinics an traditional time, at improved iron Dialysate to outcomes for And
the for the recommendation, or On Triferic Dialysate payment would – will finalized recommendation preliminary dialysis. J-code & Services, you reimbursed describes claims help the provide solution. about separate this J-code Dialysate processing for Medicare CMS, the Medicare CMS, within XX, Medicaid Centers reminder, be very or a finalized, preliminary and J-code, with JXXXX, connection a or April powder CMS from bundle. the As issued existing for for coding which products. that bundle Triferic additional case, establish packet, Healthcare packet powder finalized, We're would this and in with within a Common the be that Coding for Triferic Dialysate JXXXX it this Code a powder Procedure or treasurer new from Even the potential a reimbursed would will HCPCS which result clarity would separate recommendation distinct preliminary to packet. for unique this be pleased System If level In J-code.
special which formulation me protocol to let assessment of XXX(b)X was Now FDA I.V. several the plan to pursuant a drug developed turn application I.V. weeks, Triferic, Triferic. the In to for file we or with next the new a SPA.
which positive indicated to is As to separate the be would eligible formulation between for of Annual to the the TDAPA Triferic I.V. The for I.V. patients Triferic Triferic by equivalency under groundwork I.V. Dialysis SPA, study, review. to this we separate Triferic the evaluating for Triferic. And will an March, same transitional Triferic two we're reimbursement And and in upcoming advancing acceptable the payments of peritoneal Triferic from iron that approach be a support months. of that our eligible Dialysate the NDA and I.V. evaluating demonstrated data One add-on of or studies. for PD or quantity other anticipate supported NDA study The dialysate data it for the is meaning part payment Triferic drug portfolio we of FDA building delivers And note approved. if presented equivalence infrastructure Dialysate Triferic Conference. that subject at and the our dialysate demonstrated adjustment approval lay equivalence the Triferic Triferic filing. will XX dialysate be I.V. to support that from extension CMS will
global opportunity existing would the utilize use Triferic. believe bags now to dialysis Predominantly especially large is with bicarbonate for We the many and me easily Europe China. protocols markets opportunity So dialysis clinics global compelling as for Triferic or dry the I.V. integrate as that monitors turn such cartridges and thus I.V. let Triferic. in
two partners both and we results months hemodialysis of studies. our In now this bring identify outside and U.S. is As significant made for population the studies with needed initiated the PK completed a growing market. partner work commercialization and reminder, have Triferic expect and over these where China, progress. XXX,XXX exceeds our few enrollment Biopharmaceutical And have the rapidly, therapeutic Wanbang we shortly. has to last to strategy is And to of development the the
depending studies, Following approval of a partner meeting in with the the completion that XXXX. be outcome of And these a regulatory file to for pre-NDA our have to the meeting, CFDA. in may expect we equivalent of the on position Wanbang later
believe agreement for We in and important And that research Triferic attractive and Our the plus indicated to insights into countries. key how low of range. we’re upon regarding $X to gave active potential milestone we We're current including to in the market and Japan, Wanbang of million clinicians research $XX for completed regulatory might market sales XXX,XXX. adopt with a identify sales in Triferic we're license other European our partnering EU more also and activities. than the – Triferic support have an will this market discussions patient royalty among the hemodialysis attractive with for for recently provides up work mid continuing potential we opportunity pricing million dynamics research Overall, to based in the partners. in and a population payments, another that Europe, with approval, research and net advanced to discussions XX% Europe things us in
that partnership payable payments mix would is Canada, for filed. a In if EU agreements ready milestone payments, to and of upfront I.V. Japan, include dossier For expect royalties be nearly completed us. both to the we Triferic these and our
Our with an to there in a on of licensing Canada. the agreement Triferic us economics realize majority provides opportunity sales of
players our sales. price expansion financials. both to quarter that for we Triferic. ahead of the actually with our concentrate is We're also business, about having account strategic CFO, concentrates excited And the to the with and currently to have summary, companies including first Baxter Turning turn I'll call development of exploring We made in potential key U.S. improve base, portfolio. to our substantially and to progress in the customer Angus? economics opportunities seat of the players us Smith, quarter the over all including the with first operating review of the concentrates opportunities have and and current at DaVita industry, our Angus a further efficiencies table our both therapeutic we around now opportunities now business, and to increases, of amounts internationally. significant our the of in XXXX, concentrates through we're dialysis supply key these
